Korean Drug Co., Ltd. (KOSDAQ: 014570)

Korean Drug Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	5,195	11,689	3,426	4,841	7,068	6,271
Short-Term Investments	14,931	5,067	22,990	-	-	-
Trading Asset Securities	-	-	-	23,039	15,162	5,255
Cash & Short-Term Investments	20,126	16,756	26,416	27,881	22,230	11,526
Cash Growth	-45.36%	-36.57%	-5.25%	25.42%	92.87%	33.69%
Accounts Receivable	25,228	27,854	31,196	28,501	27,880	28,040
Other Receivables	129.8	154.04	264.21	481.69	13.67	40.26
Receivables	25,358	28,008	31,460	28,983	27,894	28,080
Inventory	22,284	18,341	13,775	12,894	10,744	11,839
Prepaid Expenses	35.15	29.68	15.8	14.88	12.11	10.9
Other Current Assets	741.74	291.26	949.19	677.81	2,075	1,271
Total Current Assets	68,544	63,426	72,617	70,450	62,956	52,727
Property, Plant & Equipment	22,523	22,999	18,607	13,999	13,784	14,849
Long-Term Investments	271.39	261.49	363.89	1,353	2,610	4,714
Other Intangible Assets	235.39	362.8	490.55	263.02	672.79	650.11
Long-Term Accounts Receivable	0	-	-	-	-	-0
Long-Term Deferred Tax Assets	722.46	1,015	1,163	820.32	307.16	-
Other Long-Term Assets	1,230	1,645	1,276	1,728	3,015	2,909
Total Assets	93,526	89,709	94,516	88,613	83,345	75,850
Accounts Payable	2,800	1,921	4.55	3,213	2,662	3,066
Accrued Expenses	806.56	1,951	1,896	1,131	974.24	760.84
Current Portion of Leases	57.53	51.31	59.47	39.07	45.85	54.28
Current Income Taxes Payable	1,211	2,192	1,499	2,151	1,788	548.75
Other Current Liabilities	5,108	3,786	3,953	3,796	4,301	4,147
Total Current Liabilities	9,983	9,902	7,412	10,329	9,771	8,577
Long-Term Leases	14.73	16.26	21.73	15	6.16	25.88
Long-Term Deferred Tax Liabilities	-	-	-	-	-	10.93
Other Long-Term Liabilities	2,338	2,355	2,107	1,579	2,697	2,186
Total Liabilities	13,163	12,619	9,804	11,923	12,474	10,800
Common Stock	5,500	5,500	5,500	5,500	5,500	5,500
Additional Paid-In Capital	3,430	3,430	3,431	3,430	3,419	3,413
Retained Earnings	72,976	69,724	77,364	69,345	62,488	56,636
Treasury Stock	-1,543	-1,563	-1,583	-1,586	-536.16	-499.33
Comprehensive Income & Other	-0	-0	-0	0	0	0
Shareholders' Equity	80,363	77,090	84,713	76,690	70,871	65,050
Total Liabilities & Equity	93,526	89,709	94,516	88,613	83,345	75,850
Total Debt	72.26	67.57	81.2	54.07	52.01	80.17
Net Cash (Debt)	20,054	16,688	26,335	27,826	22,178	11,446
Net Cash Growth	-45.42%	-36.63%	-5.36%	25.47%	93.77%	32.76%
Net Cash Per Share	1866.65	1547.64	2441.99	2548.06	2040.10	1048.97
Filing Date Shares Outstanding	10.79	10.79	10.78	10.78	10.89	10.89
Total Common Shares Outstanding	10.79	10.79	10.78	10.78	10.89	10.89
Working Capital	58,561	53,524	65,205	60,121	53,184	44,150
Book Value Per Share	7448.26	7146.81	7855.42	7111.75	6507.00	5970.82
Tangible Book Value	80,128	76,727	84,222	76,427	70,198	64,400
Tangible Book Value Per Share	7426.44	7113.17	7809.93	7087.35	6445.23	5911.15
Land	7,681	7,681	7,681	5,748	5,748	5,748
Buildings	6,900	14,955	11,264	11,264	11,006	11,006
Machinery	6,226	9,974	7,215	7,387	6,845	6,635
Construction In Progress	311.5	969.41	3,376	-	3.6	410.13

Source: S&P Capital IQ. Standard template. Financial Sources.